Plasma for direct therapeutic use, for today and tomorrow: A short critical overview

Garraud, Olivier; Aubron, Cécile; Ozier, Yves; Coppo, Paul; Tissot, Jean‐Daniel

doi:10.1016/j.tracli.2018.07.007

Cited by 8 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In July 2014 following an order of The Court of Justice of the European Union (CJEU), the high administrative court (Conseil d'Etat) decided that the SD-FFP was a pharmaceutical product and was ruled out of the EFS monopoly. The decision by the "Agence Nationale de Sécurité du Médicament et des Produits de santé" (ANSM) to approve on February 2, 2016 the marketing of OctaplasLG® in France marked a milestone and a very debated paradigm shift [14]. Since January 31, 2015, the labile component SD-FFP collected by the EFS has been discontinued.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of plasma exchange using a double viral inactivated and prion reduced solvent/detergent fresh frozen plasma for the treatment of thrombotic microangiopathy: The first French experience in a single center

Poullin

Delmotte

Sanderson

et al. 2020

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Background: Octaplas LG® is the first plasma with marketing authorisation, available in France only since February 2016. This is a double viral inactivated and prion reduced solvent/detergent fresh frozen plasma. Clinical data on Octaplas LG® use in thrombotic microangiopathy (TMA) remains very limited. In May 2017, we were the first hospital in France to benefit of this new plasma product now dispensed by hospital pharmacies. We present a prospective review of all therapeutic plasma exchange (TPE) procedures for TMA patients in our hospital to evaluate the new delivery circuit, the efficacy and the adverse events (AE) related to this plasma. Study design and methods: We prospectively reviewed 166 TPE procedures where Octaplas LG® was used as replacement fluid in 15 consecutive TMA patients required TPE in our hospital from May 2017 until December 2018. Results: The total replacement plasma volume administered was 763 L (3818 units) with a median on 32 L (range 6-157) per episode. Remission was achieved in all cases after a median of 7 TPE per patient's episode. No exacerbation nor relapse were noted. One patient presented a grade 1 citrate reaction, and another patient an allergic reaction. We deplored pulmonary embolism in 2 patients. Conclusion: In our experience OctaplasLG® was well-tolerated and was effective at inducing a full clinical remission. Although two PE were noted, the relationship to OctaplasLG® in unclear. The new dispensing circuit through the hospital pharmacy has proven to be safe and efficient.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of plasma exchange using a double viral inactivated and prion reduced solvent/detergent fresh frozen plasma for the treatment of thrombotic microangiopathy: The first French experience in a single center

Poullin

Delmotte

Sanderson

et al. 2020

Transfusion and Apheresis Science

View full text Add to dashboard Cite

show abstract

“…The biochemical profile of the blood characterizes the processes of exchange, absorption, and excretion of substances in the poultry's body (Garraud et al, 2018). Changes in the levels of biochemical indicators of blood serum are the results of the work of internal organs and homeostasis in general (Olanrewaju et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Biochemical screening of Hisex brown cross chickens after multiple vaccinations

Budnik,

Guralska

2023

Ukr. Jour. of Vet. and Agr. Sci.

View full text Add to dashboard Cite

It is impossible to imagine the epizootic well-being of poultry without immunoprophylaxis. Today, there are many vaccines to prevent infectious diseases in poultry. Our work aimed to determine how repeated vaccination affects the biochemical parameters of poultry serum. The post-vaccination changes in the protein, lipid, and enzyme metabolism of the poultry of the experimental group, which received repeated vaccine prophylaxis, are highlighted in the work. The obtained blood serum samples on the 1st, 15th, 25th, 50th, 75th, 100th, and 120th days of the chickens' life were analyzed using a semi-automatic biochemical analyzer for the content of glucose, total protein, albumins, globulins, bilirubin, creatinine, uric acid, and alpha-amylase activity, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, alkaline phosphatase, gamma glutamine transferase, and creatinine kinase. The conducted studies established an increase in indicators in the research group of 100-day-old chickens after the last vaccine prophylaxis complex compared to the control group, namely: hyperpotenemia by 8.6 %, hyperbilirubinemia by 19.6 %, hyperglycemia by 20.3 %, hyperenzymemia of alanine aminotransferase by 31 %, gamma glutamine transferase by 21.2 %, aspartate aminotransferase by 7.9 %, alpha-amylase by 3.9 %, alkaline phosphatase by 11.9 %, lactate dehydrogenase by 18.2 %. In connection with this, we can assume the stimulation of biochemical processes in the poultry's body against the background of vaccine prophylaxis.

show abstract

“…Plasma is transfused to patients to treat and prevent coagulopathies, to replace labile coagulation factors during massive transfusion, liver diseases, or is a treatment for patients with thrombotic microangiopathies often as plasma exchange therapy [ 1 , 2 ]. Transfused plasma needs to be ABO blood group compatible because anti-A and anti-B IgM and IgG antibodies (isoagglutinins) can cause adverse effects in recipients expressing the cognate antigens on endothelium and red cells [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Plasma Isoagglutinin Depletion for Blood Group Independent Plasma Transfusion

Raster¹,

Jacob²,

Greinacher³

et al. 2022

Transfus Med Hemother

View full text Add to dashboard Cite

Background: Plasma transfusion is one of the basic treatments in patients with major blood loss. The anti-A and anti-B antibodies contained in the plasma demand ABO blood group compatibility. This is limiting the use of plasma in emergency situations and can cause a shortage in the supply of plasma of certain blood groups. We developed a method for anti-A and anti-B depletion by adsorbing plasma isoagglutinins using red blood cells. Materials and Methods: Three units of fresh frozen plasma were thawed after quarantine storage, pooled, and an aliquot of red cell concentrate was added. After 2 h of incubation at room temperature antibody-red-cell complexes were removed by centrifugation, the isoagglutinin-depleted plasma was split into three units and deep frozen. Isoagglutinin titers, free hemoglobin, residual red cells, clotting factor activity, and sterility of plasma units were determined after isoagglutinin depletion and a double freeze-thawing procedure. Results: Anti-B titers in group A plasma were reduced from values of 1:64 to 1:1 or lower, anti-A titers in group B plasma decreased from values of 1:128 to at least 1:16. Postprocedure clotting factor activities were preserved with 88.0 ± 7.3% (factor V), 106.9 ± 11.4% (factor VIII), and 84.0 ± 7.5% (factor XI) fulfilling the quality control requirements. No residual red cells were found, but free hemoglobin slightly increased to 53.7 ± 5.2 μmol/L. All units were sterile. Discussion: We described a method for the production of anti-A- and anti-B-depleted plasma in a closed system that uses standard equipment. The resulting isoagglutinin-depleted plasma may allow for blood group independent plasma transfusion.

show abstract

Plasma for direct therapeutic use, for today and tomorrow: A short critical overview

Cited by 8 publications

References 29 publications

Efficacy and safety of plasma exchange using a double viral inactivated and prion reduced solvent/detergent fresh frozen plasma for the treatment of thrombotic microangiopathy: The first French experience in a single center

Efficacy and safety of plasma exchange using a double viral inactivated and prion reduced solvent/detergent fresh frozen plasma for the treatment of thrombotic microangiopathy: The first French experience in a single center

Biochemical screening of Hisex brown cross chickens after multiple vaccinations

Plasma Isoagglutinin Depletion for Blood Group Independent Plasma Transfusion

Contact Info

Product

Resources

About